glp-1 cardiovascular outcomes trial results august 2025 An Observational Study of of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists Cardiovascular Risks after GLP-1 Discontinuation
Description
Marre M, Shaw J, Brndle M, Bebakar WM, Kamaruddin NA, Strand J, et al
Unlike some medications that require a spike in your bloodstream to coincide with a meal or an activity, the active ingredient in Wegovy, semaglutide, works by maintaining a steady presence in your system over several days
Medication is shipped directly from our partner compounding pharmacy
In most cases, weight loss resumes once the new medication reaches therapeutic levels and the body adapts to the different receptor activation pattern
(2024, February 29)
Consent to Participate Informed consent was obtained from all individual participants included in the study
